Compare AbbVie Inc (ABBV) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Live Nation Entertainment, Inc. — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while Live Nation Entertainment, Inc. trades at $182.39 (market cap $42.80B). The key difference: AbbVie Inc is far larger — about 10.5× Live Nation Entertainment, Inc.'s market cap, and AbbVie Inc pays a 2.72% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | LYV | |
|---|---|---|
Market Cap | $449.91B | $42.80B |
Sector | Health | Industrials |
52-Week High | $261.07 | $186.59 |
52-Week Low | $184.85 | $125.61 |
Enterprise Value | $513.38B | $44.31B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
Live Nation (LYV) trades at $183.92, down 1.43% with a bullish technical signal despite recent earnings misses. The stock shows strong analyst support with 88.6% buy ratings and a $194 consensus target. Revenue growth remains solid at $25.2B for 2025, though profitability metrics are weak with a 0.33% net margin and negative ROE. Recent news highlights strong concert demand and strategic initiatives.
Outlook remains positive driven by live event recovery and ticketing dominance, but elevated valuation ratios and profitability challenges present risks. The stock faces headwinds from legal expenses and consumer spending pressures, requiring careful monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
